Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

NCT03549351 · clinicaltrials.gov ↗

TERMINATED

Status

51

Enrollment

OTHER

Sponsor class

Stopped Study turned out no longer feasible

Conditions

Leukemia, Myeloid, Acute

Interventions

OTHER: Measurable residual disease measured by flow cytometry

Sponsor

University Hospital Heidelberg

Collaborators

[object Object]
[object Object]